Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
There is overwhelming evidence that optimal adjuvant endocrine therapy for hormone sensitive breast cancer in postmenopausal women should include a third generation aromatase inhibitor (AI). On current evidence, adjuvant anstrozole or letrozole should be used upfront in such patients especially in t...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1586206/ |